AbbVie received European Commission approval for Rinvoq to treat giant cell arteritis, expanding its market reach and strengthening its immunology portfolio [2], [5], [9]. Despite this positive news and being highlighted as a strong dividend stock [6], ClearBridge Growth Strategy sold its AbbVie holdings due to concerns about slowing growth post-Humira exclusivity loss [1]. AbbVie updated its full-year adjusted earnings guidance to $11.99-$12.19 per share, anticipating a $248 million charge for acquired R&D [11]. While recent stock performance has declined [3], future earnings and revenue projections remain positive [3], and a temporary reprieve from potential pharmaceutical import tariffs offers some relief [8]. An executive's planned sale of $12.4 million in stock adds some uncertainty [13].

Tesla faces increasing competition from BYD, which has surpassed Tesla in key performance metrics including sales volume, revenue, and stock performance [1], [4]. European sales slumped significantly in April due to competition and negative sentiment towards CEO Elon Musk [6]. While Musk has pledged to focus more on Tesla after reducing government commitments [7], [8], [9], the company reported declining Q1 profits and deliveries [7], [9] and faces challenges in the autonomous vehicle market from competitors like Waymo [2], [10]. Despite these headwinds, Tesla remains a popular investment [5], [9], and Musk's upcoming appearance at the Milken conference may offer an opportunity to address investor concerns [3]. A Tesla director also recently sold a significant amount of stock [11].

AEHR Test Systems (AEHR) reported strong Q3 2025 financial results, exceeding revenue and earnings expectations, driven by diversification into AI processor burn-in and other markets [3], [5], [6]. However, the company revised its fiscal 2025 guidance downwards due to tariff concerns and a slower recovery in the silicon carbide market, leading to increased inventory levels [1]. Despite this, management remains optimistic about long-term growth prospects, citing strong fundamentals, a healthy backlog, and secular demand [1]. The company's Q3 SEC filing revealed increased revenue for the three months but decreased revenue for the nine months compared to the prior year, alongside decreased gross margins and ongoing lawsuits [12]. While AEHR secured new orders for AI processor burn-in systems and expanded into diverse sectors [3], [5], high short interest and negative market sentiment pose challenges [10].

Schlumberger (SLB) is divesting parts of ChampionX to address UK regulatory concerns regarding their $7.8 billion merger, expecting the deal to close in Q2 or early Q3 2025 [4], [9]. While the company's stock has declined recently, underperforming the S&P 500 [2], it is considered undervalued compared to peers [2], [5]. Despite downward revisions to earnings estimates [2], SLB consistently beats expectations [3] and is projected to grow revenue in the current and next fiscal years [2], [5]. The company continues to invest in geothermal energy [1] and secured a significant drilling contract with Woodside Energy [7], showcasing its technological leadership. Upcoming Q1 2025 earnings will be released on April 25th [6].